Home Physical Sciences Crystal structure of N-(4-acetylphenyl)-2-(6-methoxynaphthalen-2-yl)propanamide, C22H21NO3
Article Open Access

Crystal structure of N-(4-acetylphenyl)-2-(6-methoxynaphthalen-2-yl)propanamide, C22H21NO3

  • Li-wei Han and Qing Zhang EMAIL logo
Published/Copyright: August 21, 2025

Abstract

C22H21NO3, orthorhombic, P212121 (no. 19), a = 5.1909(2) Å, b = 15.8945(8) Å, c = 20.9637(11) Å, V = 1729.65(14) Å3, Z = 4, Rgt(F) = 0.0266, wRref(F 2 ) = 0.0683, T = 100(2) K.

CCDC no.: 2465536

The molecular structure is shown in the figure. Table 1 contains the crystallographic data and the list of the atoms including atomic coordinates and displacement parameters can be found in the cif-file attached to this article.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.12 × 0.11 × 0.10 mm
Wavelength: Mo Kα radiation (0.71073 Å)
μ: 0.09 mm−1
Diffractometer, scan mode: Bruker APEX-II, φ and ω scans
θmax, completeness: 27.5°, 100 %
N(hkl)measured, N(hkl)unique, Rint: 75157, 3968, 0.029
Criterion for Iobs, N(hkl)gt: Iobs > 2 σ(Iobs), 3,877
N(param)refined: 238
Programs: Bruker, 1 Olex2, 2 SHELX 3

1 Source of materials

Naproxen acylchloride was synthesized according to the literature method. 4 4–Aminoacetophenone (0.01 mol, 1.35 g) and 4-(dimethylamino)-pyridin (DMAP, 0.0015 mol, 0.18 g) were dissolved in dry tetrahydrofuran (20 mL) and triethylamine (0.015 mol, 2 mL). The solution of naproxen acylchloride in dry tetrahydrofuran was dropwise added at 0 °C. The reaction mixture was stirred for 2 h at room temperature. The reaction mixture was filtrated to remove the solid and the filtrate was concentrated under vacuum to remove the solvent. The residue was dissolved in dichloromethane, successively washed with 5 % NaOH solution and water to pH = 7, and dried with anhydrous Na2SO4. The solution was filtrated, and concentrated under vacuum to obtain crude product. The crude product was purified by recrystallization in ethanol. The single crystals were obtained from tetrahydrofuran solution.

2 Experimental details

Coordinates of hydrogen atoms were refined with constraints or restraints. The Uiso values were set to be 1.5Ueq of the carrier atom for methyl H atoms and 1.2Ueq for the remaining H atoms.

3 Comment

Naproxen is one of the most widely prescribed drugs for the treatment and management of inflammatory diseases. Long term use of naproxen can cause serious adverse reactions, such as erosion, narrowing, bleeding, and perforation in the gastrointestinal tract. The pharmacological effects of naproxen are related to the inhibition of COX-1 and COX-2 enzymes. However, due to poor selectivity, naproxen is associated with severe gastrointestinal toxicity. COX-1 inhibition leads to depletion of the gastrointestinal mucosa, which is related to gastrointestinal toxicity. In addition, naproxen contains a free carboxyl group, which, when ionized, leads to an increase in acidity, a decrease in gastric pH, and complicates the problem. 5 , 6 Research has shown that using naproxen as a prodrug can reduce the gastrointestinal side effects of naproxen and improve its bioavailability. 7 In this study, we prepared a new prodrug of naproxen that masked the free carboxylic acid groups of naproxen, thereby reducing related side effects.

The title compound contained one benzene ring and one naphthalene ring. The C=O double bond lengths in the molecule are 1.2297(17) Å (C14=O2) and 1.2197(18) Å (C21=O3), respectively, exhibiting the double bond character (see the Figure). The C–N bond lengths are 1.3628(18) Å (C14–N1) and 1.4117(17) Å (C15–N1), respectively. The dihedral angles of ring 1 (C2–C3–C4–C5–C6–C7) and ring 2 (C5–C4–C8–C9–C10–C11), ring 1 (C2–C3–C4–C5–C6–C7) and ring 3 (C15–C16–C17–C18–C19–C20), ring 2 (C5–C4–C8–C9–C10–C11) and ring 3 (C15–C16–C17–C18–C19–C20) are 1.920°, 56.277°, 55.668°, respectively. The other bond distances and angles are in their normal ranges according to the previously reported compounds. 8 , 9 , 10


Corresponding author: Qing Zhang, Dongying Hospital of Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Dongying, China, E-mail:

  1. Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Conflict of interest: The authors declare no conflicts of interest regarding this article.

References

1. Bruker. SAINT and SADABS; Bruker AXS Inc.: Madison, Wisconsin, USA, 2000.Search in Google Scholar

2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Search in Google Scholar

3. Sheldrick, G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Search in Google Scholar

4. Huang, Z. J.; Carlos, A. V.; Khaled, R. A. A.; Morshed, A. C.; Julie, A. R.; Jenna, F. D.; Bruce King, S.; Edward, E. K. Ethanesulfohydroxamic Acid Ester Prodrugs of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Synthesis, Nitric Oxide and Nitroxyl Release, Cyclooxygenase Inhibition, Anti-Inflammatory, and Ulcerogenicity Index Studies. J. Med. Chem. 2011, 77, 1356–1364.10.1021/jm101403gSearch in Google Scholar PubMed

5. Yoshikawa, Y.; Naito, Y.; Tomii, T.; Kaneko, T.; Iinuma, S.; Ichikawa, H.; Yasuda, M.; Takahashi, S.; Kondo, M. Role of Active Oxygen, Lipid Peroxidation, and Antioxidants in the Pathogenesis of Gastric Mucosal Injury Induced by Indomethacin in Rats. Gut 1993, 34, 732–737; https://doi.org/10.1136/gut.34.6.732.Search in Google Scholar PubMed PubMed Central

6. Chandiran, S.; Vyas, S.; Sharma, N.; Sharma, M. Synthesis and Evaluation of Antioxidant-S-(+)-ibuprofen Hybrids as Gastro Sparing NSAIDs. Med. Chem. 2013, 9, 1006–1016; https://doi.org/10.2174/1573406411309070015.Search in Google Scholar PubMed

7. Zawilska, J. B.; Wojcieszak, J.; Olejniczak, A. B. Prodrugs: A Challenge for the Drug Development. Pharmacol. Rep. 2013, 65, 1–14; https://doi.org/10.1016/s1734-1140(13)70959-9.Search in Google Scholar PubMed

8. Hannah, E. K.; Lorna, K. S.; Kuthuru, S.; Paul, H.; Ivana, R. E. Structure and Physicochemical Characterization of a Naproxen-Picolinamide Cocrystal. Acta Crystallogr. 2017, C73, 168–175.10.1107/S2053229616011980Search in Google Scholar PubMed PubMed Central

9. Fiorella, B.; Miroslav, F.; Massimo, S. Complex of a Lisuride Derivative and (S)-Naproxen. Acta Crystallogr. 1997, C53, 136–140.10.1107/S0108270196009870Search in Google Scholar

10. Pike, S. J.; Telford, R.; Male, L. Louise Male, Reversible Conformational Switching of a Photo-Responsive Ortho-azobenzene/2,6-Pyridyldicarboxamide Heterofoldamer. Org. Biomol. Chem. 2023, 21, 7717; https://doi.org/10.1039/D3OB01137B.Search in Google Scholar

Received: 2025-05-13
Accepted: 2025-06-19
Published Online: 2025-08-21
Published in Print: 2025-10-27

© 2025 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. New Crystal Structures
  3. Crystal structure of (S)-N-(10-((2,2-dimethoxyethyl)amino)-1,2,3-trimethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide, C25H32N2O7
  4. The crystal structure of 6,6′-difluoro-3,3′-dimethyl-5,5′-di(10H-phenoxazin-10-yl)- [1,1′-biphenyl]-2,2′-dicarbonitrile, C40H24F2N4O2
  5. Crystal structure of poly[(di-ethylenediamine-κ2N,N′)cadmium(II) tetradedocyloxidohexavanadate] (V4+/V5+ = 2/1), C4H16CdN4O14V6
  6. The crystal structure of poly[bis(dimethylformamide-κ1N)-(μ4-2′,3,3″,5′-tetrakis(trifluoromethyl)-[1,1′:4′,1″-terphenyl]-4,4″-dicarboxylato-κ4 O,O′: O″,O‴)dicadmium(II)], C27H15CdF12NO5
  7. Crystal structure of bis(μ2-ferrocenylcarboxylato-O,O′)-(μ3-oxido-κ3O:O:O)-bis(μ2-salicyladoximato-κ2N,O,O′)-(μ2-isopropoxo)-tris(isopropoxy-κ1O trititanium(IV)), C48H55N2O13Fe2Ti3
  8. Crystal structure of 3-(diethylamino)-7,9,11-trimethyl-8-phenyl-6H,13H-12λ4,13λ4-chromeno[3′,4′:4,5]pyrrolo[1,2-c]pyrrolo[2,1-f][1,3,2]diazaborinin-6-one, C28H26BF2N3O2
  9. The crystal structure of catena-poly[aqua-μ2-2-nitro-benzene-1,3-dicarboxylato-κ2O,O′)-(1,10-phenanthroline-κ2N,N′)-zinc(II)], C20H13N3O7Zn
  10. Crystal structure of poly[diaqua-{μ3-1-(3-carboxylatophenyl)-4-oxo-1,4-dihydropyridazine-3-carboxylato-κ4O,O′:O′′:O′′′′}manganese(II)] hydrate
  11. Crystal structure of N′-((1-hydroxycyclohexyl)(phenyl)methyl)-2-methoxybenzohydrazide methanol solvate, C22H28N2O4
  12. The cocrystal of caffeic acid — progesterone — water (1/2/1), C51H70O9
  13. Crystal structure of (((oxido(quinolin-6-yl)methoxy)triphenyl-λ5-stibanyl)oxy)(quinolin-7-yl)methanolate
  14. Crystal structure of [(E)-6′-(diethylamino)-2-(2-(((E)-pyren-1-ylmethylene)amino)ethyl)-4′-(2-((E)-1,3,3-trimethylindolin-2-ylidene)ethylidene)-1′,2′,3′,4′-tetrahydrospiro[isoindoline-1,9′-xanthen]-3-one]-methanol, solvate C57H56N4O3
  15. The crystal structure of 1-(acridin-9-yl)pyrrolidine-2,5-dione, C17H22N2O2
  16. Crystal structure of N-(4-acetylphenyl)-2-(6-methoxynaphthalen-2-yl)propanamide, C22H21NO3
  17. The crystal structure of 5,10,15,20-tetrakis(4-(1H-1,2,4-triazol-1-yl)phenyl)porphyrin, C52H34N16
  18. Crystal structure of hexacarbonyl-μ2-[phenylmethanedithiolato-κ4S:S,S′:S′]diiron (Fe–Fe) C13H6Fe2O6S2
  19. Crystal structure of diiodo-bis(1-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-1H-benzo[d][1,2,3]triazole-κ1N)cadmium(II), C34H34CdI2N10
  20. Crystal structure of (E)-(3-(3-bromophenyl)acryloyl)ferrocene, C19H15BrFeO
  21. Crystal structure of catena-poly(μ2-6-chloropyridine-2-carboxylato-κ3N,O:O′)(6-chloropyridine-2-carboxylato-κ2O,N)copper(II), C12H6Cl2N2O4Cu
  22. Crystal structure of poly[diaqua-μ 3-(5-(3,5-dicarboxy-2,4,6-trimethylbenzyl)-2,4,6-trimethylisophthalato)-κ 6O,O′:O″,O‴:O‴′,O‴″) terbium(III)-monohydrate], C23H28TbO12
  23. Crystal structure of (E)-2-(((5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene)amino)-3′,6′-dihydroxyspiro[isoindoline-1,9′-xanthen]-3-one – ethanol (1/2), C35H33ClN4O6
  24. The crystal structure of 3-(5-amino-3-phenylisoxazol-4-yl)-4-chloro-3-hydroxyindolin-2-one, C17H12ClN3O3
  25. The crystal structure of dimethylammonium 4-[2-(4-fluorophenyl)-4, 5-diphenyl-1H-imidazol-1-yl]benzenesulfonate, C29H26FN3O3S
  26. Crystal structure of (R)-2-ammonio-3-((5-carboxypentyl)thio)propanoate
  27. Crystal structure of 4-cyclohexyl-5-(thiophen-2-yl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, C12H15N3S2
  28. The crystal structure of 4,6-bis(dimethylamino)-2-fluoroisophthalonitrile, C12H13FN4
  29. Hydrogen bonding in the crystal structure of nicotin-1,1′-dium tetrabromidomanganate(II)
  30. The crystal structure of bis(2-bromobenzyl)(2-((2-oxybenzylidene)amino)-4-methylpentanoato-κ3N, O,O′)tin(IV), C27H27Br2NO3Sn
  31. Crystal structure of (E)-(3-(p-tolyl)acryloyl)ferrocene, C20H18FeO
  32. Crystal structure of (E)-7-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C21H22FN3O
  33. Crystal structure of (E)-7-methoxy-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)methylene)-3,4-dihydronaphthalen-1(2H)-one, C22H25N3O2
  34. The crystal structure of poly(bis(μ2-1,3,5-tri(1H-imidazol-1-yl)benzene-κ2N:N′)-(μ2-2,3,5,6-tetrafluoroterephthalato-κ2O:O′)-manganese(II), C38H24F4N12O4Mn
  35. Crystal structure of (3,4-dimethoxybenzyl)triphenylphosphonium bromide ethanol solvate, C29H32BrO3P
  36. Crystal structure of tetraethylammonium hydrogencarbonate – (diaminomethylene)thiourea – water (2/1/3)
  37. Crystal structure of N, N-Dimethyl-N′-tosylformimidamide, C10H14N2O2S
  38. The crystal structure of ethyl 2-methyl-5-oxo-4-(2-methoxyphenyl)-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate, C20H23N2O4
  39. Crystal structure of bis(μ2-1,5-bis[(E)-1-(2-hydroxyphenyl)ethylidene] thiocarbonohydrazide)-bis(dimethylformamide)-dizinc(II) dimethylformamide solvate, C40H46N10O6S2Zn2⋅C3H7NO
  40. Crystal structure of azido-κ1N{hydridotris(3-tert-butyl-5-methylpyrazol-1-yl)borato-κ3N,N′,N″}copper(II), C24H40BCuN9
  41. The crystal structure of fac-tricarbonyl(1,10-phenanthroline-κ2N,N′)-(azido-κ1N)rhenium(I), C15H8N5O3Re
  42. Crystal structure of 4-((triphenylphosphonio)methyl)pyridin-1-ium tetrachloridozincate(II), C24H22Cl4NPZn
Downloaded on 3.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2025-0227/html?recommended=sidebar&srsltid=AfmBOopnIKiP91QrfHLGrida2Wbcidu98_xRjpuuWndwBC1wVNb4R4bm
Scroll to top button